International Journal of Molecular Biotechnological Research Review Article
REVIEW OF PHARMACOEPIGENETICS: BRIDGING EPIGENETICS AND PERSONALIZED MEDICINE
Abstract
Pharmacoepigenetics is an emerging field that explores how alterations in gene expression, independent of DNA sequence changes, influence individual responses to drugs. Unlike pharmacogenetics, which focuses primarily on genetic variation, pharmacoepigenetics integrates genetic, environmental, and lifestyle factors to explain interindividual differences in drug efficacy, toxicity, and resistance. Key epigenetic mechanisms including DNA methylation, histone modifications, non-coding RNAs, and RNA methylation play critical roles in regulating drug metabolism and therapeutic outcomes. This review highlights the growing clinical relevance of pharmacoepigenetics in cancer, neurological, and cardiovascular disorders, where epigenetic biomarkers and targeted therapeutics are reshaping treatment strategies. Epigenetic agents such as DNMT, HDAC, and EZH2 inhibitors can restore normal gene expression and enhance drug sensitivity. Despite these advances, challenges remain in biomarker validation, data interpretation, and establishing causal links between epigenetic modifications and treatment response. Integration of CRISPR-based epigenome editing, artificial intelligence, and multi-omics approaches is anticipated to accelerate the clinical translation of pharmacoepigenetic insights, enabling safer, more effective, and truly personalized therapies.
Keywords
References (1)
- Dupont C, Armant DR, Brenner CA. Epigenetics: definition, mechanisms and clinical perspective. Semin Reprod Med. 2009;27(5):351-357. doi:10.1055/s-0029-1237423. 2. Laufer, B.I., Singh, S.M. Strategies for precision modulation of gene expression by epigenome editing: an overview. Epigenetics & Chromatin 8, 34 (2015). https://doi.org/10.1186/s13072-015-0023-7. 3. Rasool, M., Malik, A., Naseer, M.I. et al. The role of epigenetics in personalized medicine:challenges and opportunities. BMC Med Genomics 8 (Suppl 1), S5 (2015).https://doi.org/10.1186/1755-8794-8-S1-S5. 4. Smith DA, Sadler MC, Altman RB. Promises and challenges in pharmacoepigenetics. Cambridge Prisms: Precision Medicine. 2023;1:e18. doi:10.1017/pcm.2023.6. 5. Feehley, T., O’Donnell, C.W., Mendlein, J. et al. Drugging the epigenome in the age of precision medicine. Clin Epigenet 15, 6 (2023). https://doi.org/10.1186/s13148-022-01419-z. 6. Zhou J, Li M, Wang X, et al. Drug Response-Related DNA Methylation Changes in Schizophrenia, Bipolar Disorder, and Major Depressive Disorder. Front Neurosci. 2021;15:674273. Published 2021 May 13. doi:10.3389/fnins.2021.674273. 7. Nicola M (2025) Pharmacoepigenetics: Unlocking the Role of Epigenetics in Drug Response. J Cell Mol Pharmacol 9: 262DOI: 10.4172/jcmp.1000262. 8. Yaacoub, S., Boudaka, A., AlKhatib, A. et al. The pharmaco-epigenetics of hypertension: a focus on microRNA. Mol Cell Biochem 479, 3255–3271 (2024). https://doi.org/10.1007/s11010-024-04947-9. 9. Tang, J., Xiong, Y., Zhou, H.-.-H. and Chen, X.-.-P. (2014), DNA methylation and personalized medicine. J Clin Pharm Ther, 39: 621-627. https://doi.org/10.1111/jcpt.12206 10. Rusek M, Krasowska D. Non-Coding RNA in Systemic Sclerosis: A Valuable Tool for Translational and Personalized Medicine. Genes. 2021; 12(9):1296. https://doi.org/10.3390/genes12091296 11. Si, W., Shen, J., Zheng, H. et al. The role and mechanisms of action of microRNAs in cancer drug resistance. Clin Epigenet 11, 25 (2019). https://doi.org/10.1186/s13148-018- 0587-8 P.S.G.V.P. MANDAL’S COLLEGE OF PHARMACY, SHAHADA 11 12. Liu, Z., Zou, H., Dang, Q. et al. Biological and pharmacological roles of m 6 A modifications in cancer drug resistance. Mol Cancer 21, 220 (2022). https://doi.org/10.1186/s12943-022-01680-z 13. Fan HH, Wang LQ, Liu WL, et al. Repurposing of clinically approved drugs for treatment of coronavirus disease 2019 in a 2019-novel coronavirus-related coronavirus model. Chin Med J (Engl). 2020;133(9):1051-1056. doi:10.1097/CM9.0000000000000797 14. Ocaña-Paredes B, Rivera-Orellana S, Ramírez-Sánchez D, et al. The pharmacoepigenetic paradigm in cancer treatment. Front Pharmacol. 2024;15:1381168. Published 2024 Apr 24. doi:10.3389/fphar.2024.1381168 15. Smith DA, Sadler MC, Altman RB. Promises and challenges in pharmacoepigenetics. Camb Prism Precis Med. 2023;1:e18. Published 2023 Feb 9. doi:10.1017/pcm.2023.6 16. Roberts, C.-T., Arezoumand, K.S., Kadar Shahib, A., Davie, J.R., & Rastegar, M. (2024). Epigenetics in rare neurological diseases. Frontiers in Cell and Developmental Biology, 12:1413248. 17. Grezenko, H., etc. (2023). Epigenetics in Neurological and Psychiatric Disorders. PMC Article. 18. Grech, A., West, S., & Tonna, R. (2020). Clinical relevance of pharmacoepigenetics. The Synapse : the Medical Professionals' Network, 19(3), 12-15. 19. Napoli C, Grimaldi V, De Pascale MR, Sommese L, Infante T, Soricelli A. Novel epigenetic-based therapies useful in cardiovascular medicine. World J Cardiol. 2016;8(2):211-219. doi:10.4330/wjc.v8.i2.211 20. Nalejska E, Mączyńska E, Lewandowska MA. Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther. 2014;18(3):273-284. doi:10.1007/s40291-013-0077-9 21. Hsueh, CT., Liu, D. & Wang, H. Novel biomarkers for diagnosis, prognosis, targeted therapy and clinical trials. Biomark Res 1, 1 (2013). https://doi.org/10.1186/2050-7771-1-1 22. FDA-NIH Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools) Resource [Internet]. Silver Spring (MD): Food and Drug Administration (US); 2016-. Predictive Biomarker. 2016 Dec 22. Available from: https://www.ncbi.nlm.nih.gov/books/NBK402283/ Co-published by National Institutes of Health (US), Bethesda (MD). 23. Jørgensen, J. T., & Westergaard, N. (2022). Predictive biomarkers and personalized pharmacotherapy. Expert Review of Molecular Diagnostics, 22(10), 919–922. https://doi.org/10.1080/14737159.2022.2139602 24. Nalejska E, Mączyńska E, Lewandowska MA. Prognostic and predictive biomarkers: tools in personalized oncology. Mol Diagn Ther. 2014;18(3):273-284. doi:10.1007/s40291-013-0077-9 25. Majchrzak-Celińska A, Warych A, Szoszkiewicz M. Novel Approaches to Epigenetic Therapies: From Drug Combinations to Epigenetic Editing. Genes (Basel). 2021;12(2):208. Published 2021 Jan 31. doi:10.3390/genes12020208 P.S.G.V.P. MANDAL’S COLLEGE OF PHARMACY, SHAHADA 12 26. Mottamal M, Zheng S, Huang TL, Wang G. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents. Molecules. 2015;20(3):3898-3941. Published 2015 Mar 2. doi:10.3390/molecules20033898 27. Marks PA, Xu WS. Histone deacetylase inhibitors: Potential in cancer therapy. J Cell Biochem. 2009;107(4):600-608. doi:10.1002/jcb.22185 28. Nepali, K., Liou, JP. Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends. J Biomed Sci 28, 27 (2021). https://doi.org/10.1186/s12929-021-00721-x 29. Straining R, Eighmy W. Tazemetostat: EZH2 Inhibitor. J Adv Pract Oncol.2022;13(2):158-163. doi:10.6004/jadpro.2022.13.2.7 30. Bell JT, Spector TD. DNA methylation studies using twins: what are they telling us?. Genome Biol. 2012;13(10):172. Published 2012 Oct 18. doi:10.1186/gb-2012-13-10-172 31. Molla G, Bitew M. Revolutionizing Personalized Medicine: Synergy with Multi-Omics Data Generation, Main Hurdles, and Future Perspectives. Biomedicines. 2024;12(12):2750. Published 2024 Nov 30. doi:10.3390/biomedicines12122750 32. Wang, C., Lye, X., Kaalia, R. et al. Deep learning and multi-omics approach to predict drug responses in cancer. BMC Bioinformatics 22 (Suppl 10), 632 (2021). https://doi.org/10.1186/s12859-022-04964-9 33. Johnson KB, Wei WQ, Weeraratne D, et al. Precision Medicine, AI, and the Future of Personalized Health Care. Clin Transl Sci. 2021;14(1):86-93. doi:10.1111/cts.12884 34. Syding LA, Nickl P, Kasparek P, Sedlacek R. CRISPR/Cas9 Epigenome Editing Potential for Rare Imprinting Diseases: A Review. Cells. 2020; 9(4):993. https://doi.org/10.3390/cells9040993 35. Chehelgerdi, M., Chehelgerdi, M., Khorramian-Ghahfarokhi, M. et al. Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy. Mol Cancer 23, 9 (2024). https://doi.org/10.1186/s12943-023-01925-5